- How Craig Venter Plans to Challenge Google in the Race to Enhance Human Health
Everyone thought Google was crazy for trying to find solutions to major problems facing human health. So what will they say when they discover Google isn't alone in its ambitious quest?
- Bill Gates' Dream for a Nuclear-Powered Future Is Almost Here
Like it or not, nuclear energy remains the safest and cleanest energy source. Could reactors that consume nuclear waste developed by General Electric, TerraPower, and Babcock & Wilcox make Bill Gates' dream a reality?
- How Designer Microbes and the Organism Industry Will Reshape Our World
Many investors are captivated by the future of companies such as Tesla Motors and 3-D Systems -- and the potential creation of shareholder value on a scale that will be difficult to match. But are investors overlooking an even more promising industry with a brighter future?
- Attention, Solazyme Investors: Don't Forget About Amyris
Synthetic biology pioneer Amyris discussed its full-year 2013 results after market close. Here's what investors need to know about 2013 and what you can expect from operations in 2014.
- Can Solazyme Inc Successfully Scale Biology?
Renewable oils company Solazyme recently announced the start-up of commercial operations at its Clinton, Iowa facility. The market sent shares 30% higher, but past obstacles in scaling biology at Amyris and Gevo may hint that the spike was a bit premature.
- Ford's Lightweight F-150 Can Save Americans How Much in Fuel Costs!?!
The new 2015 Ford F-150 has shed up to 700 pounds, which significantly ups the ante for automakers racing to comply with the aggressive new CAFE standards. How much could it save you in fuel costs? And how will next-generation innovations from Ford, General Motors, and Magna International further improve upon aluminum designs?
- 5 Unbelievable (but Real) Technologies Made Possible by Synthetic Biology
The synthetic biology industry has erupted in recent years. The technological breakthroughs can touch numerous industries, from health care to marijuana production.
- 3 Ways the $1,000 Human Genome Can Revolutionize Science and Medicine As We Know It
The cost to sequence a full human genome reached a critical milestone on Tuesday when Illumina announced its next-generation system will enable $1,000 tests. There are far-reaching implications for human health, but the possibilities extend beyond the doctor's office.
- KiOR Uproar: Plant Shutdown and Condoleezza Rice Resigns
Woody biomass to next-generation fuels producer KiOR updated investors on its operations in 2013 and goals for 2014. Should the hesitance of partners such as FedEx, Chevron, and Weyerhaeuser to provide additional funding make you think twice about an investment?
- How Biotech Companies Are Creating Your Next Winter Weather Snow Tires
Recent partnerships and developments in the chemical industry demonstrate that biobased chemical production isn't such an ice-cold opportunity for investors after all. It may take several years for collaborations between Genomatica and Braskem and Amyris and Michelin to scale their biological processes for renewable rubbers, but biotech snow tires are indeed on the horizon. Can you profit from the industry's disruptive shift?